...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing
【24h】

Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing

机译:小分子依诺沙星是一种癌症特异性生长抑制剂,可通过增强TAR RNA结合蛋白2介导的microRNA加工来发挥作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

MicroRNAs (miRNAs) are small RNA molecules that regulate gene expression at the posttranscriptional level and are critical for many cellular pathways. The disruption of miRNAs and their processing machineries also contributes to the development of human tumors. A common scenario for miRNA expression in carcinogenesis is emerging that shows that impaired miRNA production and/or down-regulation of these transcripts occurs in many neoplasms. Several of these lost miRNAs have tumor-suppressor features, so strategies to restore their expression globally in malignancies would be a welcome addition to the current therapeutic arsenal against cancer. Herein, we show that the small molecule enoxacin, a fluoroquinolone used as an antibacterial compound, enhances the production of miRNAs with tumor suppressor functions by binding to the miRNA biosynthesis protein TAR RNA-binding protein 2 (TRBP). The use of enoxacin in human cell cultures and xen-ografted, orthotopic, and metastatic mouse models reveals a TRBP-dependent and cancer-specific growth-inhibitory effect of the drug. These results highlight the key role of disrupted miRNA expression patterns in tumorigenesis, and suggest a unique strategy for restoring the distorted microRNAome of cancer cells to a more physiological setting.
机译:微小RNA(miRNA)是小的RNA分子,可在转录后水平调节基因表达,并且对于许多细胞途径至关重要。 miRNA及其加工机制的破坏也有助于人类肿瘤的发展。 miRNA在癌变过程中表达的常见情况正在出现,表明在许多肿瘤中,miRNA的产生受损和/或这些转录物的下调。这些丢失的miRNA中有几种具有肿瘤抑制功能,因此在恶性肿瘤中全面恢复其表达的策略将是当前抗癌治疗药库中受欢迎的补充。在这里,我们显示小分子依诺沙星,一种用作抗菌化合物的氟喹诺酮,通过与miRNA生物合成蛋白TAR RNA结合蛋白2(TRBP)结合,增强了具有肿瘤抑制功能的miRNA的产生。依诺沙星在人类细胞培养物中和异种移植,原位转移小鼠模型中的使用揭示了该药物的TRBP依赖性和癌症特异性生长抑制作用。这些结果突显了破坏的miRNA表达模式在肿瘤发生中的关键作用,并提出了一种独特的策略,可将扭曲的癌细胞的microRNAome恢复至更生理的环境。

著录项

  • 来源
  • 作者单位

    Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet, Barcelona, Catalonia, Spain;

    Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet Barcelona, Catalonia, Spain;

    Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet, Barcelona, Catalonia, Spain;

    Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet, Barcelona, Catalonia, Spain;

    Departments of Experimental Therapeutics and Cancer Genetics, M D Anderson Cancer Center, Houston, TX 77030;

    Departments of Experimental Therapeutics and Cancer Genetics, M D Anderson Cancer Center, Houston, TX 77030;

    Departments of Experimental Therapeutics and Cancer Genetics, M D Anderson Cancer Center, Houston, TX 77030 Bioinformatics Core Facility, CH-1015 Lausanne, Switzerland;

    Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet, Barcelona, Catalonia, Spain;

    Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet Barcelona, Catalonia, Spain;

    Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet, Barcelona, Catalonia, Spain;

    Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet, Barcelona, Catalonia, Spain;

    Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet, Barcelona, Catalonia, Spain;

    Department of Pathology, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute, 08907 L'Hospitalet de Llobregat, Barcelona, Spain;

    Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet Barcelona, Catalonia, Spain;

    Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet Barcelona, Catalonia, Spain;

    Departamento de Bioquimica y Biologia Molecular, Universidad de Alcala, Alcala de Henares, 28801 Alcala de Henares, Madrid, Spain;

    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215;

    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210;

    Departments of Experimental Therapeutics and Cancer Genetics, M D Anderson Cancer Center, Houston, TX 77030;

    Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet, Barcelona, Catalonia, Spain Institucio Catalana de Recerca i Estudis Avancats, 08010 Barcelona, Catalonia, Spain;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    non-coding RNA; transformation; therapy; pharmacogenetics;

    机译:非编码RNA;转型;治疗;药物遗传学;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号